Key regions: United Kingdom, Germany, France, South Korea, Italy
Suriname, a small country in South America, has been actively participating in the global effort to vaccinate its population against COVID-19. The COVID-19 Vaccines market in Suriname is developing in a way that reflects the country's unique circumstances and challenges.
Customer preferences: As in many other countries, the majority of Suriname's population prefers to receive the Pfizer-BioNTech vaccine. However, due to logistical challenges and limited supply, the country has also administered the Sinopharm and AstraZeneca vaccines. There is a growing demand for vaccines among the population, and the government has been working to increase access and availability.
Trends in the market: The COVID-19 Vaccines market in Suriname has been characterized by a slow but steady increase in vaccination rates. As of August 2021, over 20% of the population has been fully vaccinated. The government has been working to ramp up vaccination efforts, particularly in rural areas where access to healthcare and information is limited. In addition, the country has been participating in the COVAX initiative, which aims to provide equitable access to vaccines for all countries.
Local special circumstances: Suriname's unique geography and demographics have presented challenges for the country's vaccination efforts. The country has a large rural population, which can be difficult to reach with vaccines and information. In addition, the country's dense rainforest and lack of infrastructure can make transportation and distribution of vaccines challenging. The government has been working to address these challenges through targeted outreach and education campaigns.
Underlying macroeconomic factors: Suriname's economy has been heavily impacted by the COVID-19 pandemic, with a sharp decline in tourism and other sectors. The government has faced challenges in funding its vaccination efforts, and has relied on international aid and partnerships to support its efforts. In addition, the country's political and social instability has added to the challenges of vaccine distribution and uptake. Despite these challenges, the government has remained committed to vaccinating its population and has made progress in increasing access and availability of vaccines.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
